Dianthus Therapeutics, Inc. /DE/
Company Stats
- Market Cap
- $4.9B
- as of Sep 30, 2026
- Shares Outstanding
- 55.9M
- Free Float
- 67.7%
Income Statement
- Revenue
- $2.0M
- Operating Income
- -$177.9M
- Net Income
- -$162.3M
- EBITDA
- -$177.8M
Balance Sheet
- Cash & Equivalents
- $51.1M
Returns & Capital
- SBC, 3Y Avg
- $12.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $2.0M | — | — |
| FY2024 | $6.2M | — | — |
| FY2023 | $2.8M | — | — |
| FY2022 | — | -$29.4M | — |
| FY2021 | — | -$60.8M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back